Metabolomics

Dataset Information

0

Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease

ABSTRACT: Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.

INSTRUMENT(S): Liquid Chromatography MS - positive - reverse phase

PROVIDER: MTBLS2266 | MetaboLights | 2020-12-21

REPOSITORIES: MetaboLights

Json Xml

Dataset's files

Source:
Action DRS
102.mzML Mzml
103.mzML Mzml
105.mzML Mzml
106.mzML Mzml
107.mzML Mzml
Items per page:
1 - 5 of 853
altmetric image

Publications

Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control s  ...[more]

Similar Datasets

Transcriptomics Next generation sequencing reveals upregulation of the lncRNA LINC-PINT in the substantia nigra of human Parkinson's disease patients compared to control donors
2020-04-14 | GSE114517 | GEO
Transcriptomics Gene expression profiling of substantia nigra: a post-mortem study in Parkinson's disease and control subjects
2024-01-03 | E-MTAB-13295 | biostudies-arrayexpress
Transcriptomics Systematic meta-analysis and replication of genome-wide expression studies of Parkinson's disease: 3
2011-01-20 | GSE20164 | GEO
Transcriptomics Systematic meta-analysis and replication of genome-wide expression studies of Parkinson's disease: 2
2011-01-20 | GSE20163 | GEO
Transcriptomics System-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms
2014-09-01 | E-GEOD-54282 | biostudies-arrayexpress
Transcriptomics Transcriptomic dataset of neural progenitors differentiated from Parkinson's disease patient induced pluripotent stem cells with heterozygous PARK2 junction mutations transduced with a lentivector containing PARK2 cDNA.
2022-06-03 | GSE205235 | GEO
Transcriptomics Systematic meta-analysis and replication of genome-wide expression studies of Parkinson's disease: 3
2011-01-20 | E-GEOD-20164 | biostudies-arrayexpress
Genomics Epigenetic modification, as a distinctive therapeutic molecule for Parkinson’s disease gene therapy.
2025-11-30 | GSE308116 | GEO
Transcriptomics Systematic meta-analysis and replication of genome-wide expression studies of Parkinson's disease: 2
2011-01-20 | E-GEOD-20163 | biostudies-arrayexpress
Transcriptomics Transcriptome datasets of neural progenitors and neurons differentiated from induced pluripotent stem cells of healthy donors and Parkinson's disease patients with mutations in PARK2 gene
2021-08-19 | GSE181029 | GEO